Interesting - there are two significant 8-Ks I should dig into: the Vega Therapeutics acquisition and the CMS litigation resolution on Opzelura rebates. Let me read those.Let me check the most recent conference call transcripts (Goldman Sachs, June 9) for the latest management commentary closest to earnings, plus the "report second quarter" press release for date confirmation.# Incyte Corporation (INCY) — Q2 2026 Earnings Preview Report Date: Tuesday, July 28, 2026, 7:00 a.m. ET (release) / 8:00 a.m. ET (call)
Incyte heads into its second-quarter print riding a strong wave of momentum. The stock has climbed from roughly $95 at the time of the Q1 report (April 28) to nearly $119 as of July 27 — a gain of over 20% in three months — fueled by a string of positive pipeline readouts, a major litigation settlement, and a bolt-on M&A deal. The key question for tomorrow's print is whether the underlying commercial business can sustain the growth trajectory investors are now underwriting, and how management updates full-year guidance given several one-time and structural items that have emerged since Q1.
Incyte's first quarter was strong across the board. Total revenue was $1.27 billion and total net sales were $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025. Within that: - Jakafi (ruxolitinib) net sales of $758 million, an increase of 7% compared to the same period in 2025 - Opzelura (ruxolitinib) cream net sales of $143 million and Hematology and Oncology portfolio net sales of $204 million, an increase of 20% and 116%, respectively, compared to the first quarter of 2025
Profitability improved meaningfully, with GAAP diluted EPS of $1.47 (vs. $0.80 a year ago) and non-GAAP diluted EPS of $1.81 (vs. $1.16), aided by operating leverage — Ongoing operating expenses for the first quarter of 2026 increased 14% year-over-year compared to a 19% increase in ongoing revenues during the same period, leading to a continued increase in operating leverage and margins.
At the time, Incyte reaffirmed FY2026 guidance: total net sales of $4.77B–$4.94B (implying ~10–13% growth), Jakafi net sales of $3.22B–$3.27B, Opzelura of $750M–$790M, and Hematology & Oncology of $800M–$880M, alongside GAAP R&D+SG&A of $3.495B–$3.675B.
Two major corporate developments since the last print are likely to dominate tomorrow's commentary:
1. CMS/Medicaid Rebate Settlement (announced June 22). Incyte resolved a long-running dispute over whether Opzelura should be treated as a "line extension" of Jakafi for Medicaid rebate purposes. Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi, and the Company has withdrawn its lawsuit challenging the regulations. This has two effects: a one-time GAAP benefit and a structural improvement to gross margin. The Company expects to record a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026, associated with the reversal of previously established accrual balances through March 31, 2026... The Company will no longer accrue for the potential application of the line extension regulations to Opzelura and expects an improvement to Opzelura's gross-to-net on a go-forward basis. Management explicitly flagged that it plans to update financial guidance to reflect the impact of the settlement during the next scheduled earnings release — i.e., tomorrow. Expect a GAAP EPS/net income beat driven by this item, plus a likely raise to Opzelura net sales guidance.
2. Vega Therapeutics Acquisition (closed July 6). Incyte completed its purchase of Vega Therapeutics for $1.25 billion upfront (plus up to $750 million in milestones), adding VGA039 — a Phase 3 monoclonal antibody for von Willebrand disease. Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte's late-stage pipeline. Importantly for modeling Q2, We expect the transaction to be reflected as a one-time R&D expense in the third quarter and full year 2026 GAAP and non-GAAP financial results — so this hit lands in Q3, not Q2, but investors should listen for commentary on balance sheet/cash impact (Incyte ended Q1 with $4.0 billion in cash) and integration plans.
3. Leadership transition. New CFO Suketu Upadhyay (ex-Zimmer Biomet, ex-BMS) started May 4, 2026, and this will be his first full-quarter earnings call — worth watching for any early signals on capital allocation philosophy, buybacks, or expense discipline.
Incyte's narrative has shifted decisively toward "life beyond Jakafi." Recent/upcoming milestones likely to be referenced or updated tomorrow: - Povorcitinib (HS & vitiligo): NDA accepted by FDA in HS (Q1), with anticipated potential approval and launches in late-2026 in the EU and the first quarter of 2027 in the U.S. Positive Phase 3 vitiligo data was announced alongside Q1 results, and management has framed povorcitinib as a potential $500M–$1B HS franchise plus incremental vitiligo/PN upside. - INCA033989 (mutant CALR antibody): Phase 3 in essential thrombocythemia was slated to start mid-2026 following a positive FDA end-of-phase meeting; an EHA data update in June likely provided fresh detail on durability and translational biomarkers — watch for confirmation the Phase 3 ET trial has been formally initiated, and updated timing on the second-line/first-line MF programs. - INCB161734 (KRAS G12D): Phase 3 DAWN-303 trial in first-line pancreatic cancer initiated in Q1; Phase 1 combination data (chemotherapy backbone) expected in 2H26, potentially at a medical conference. - VGA039 (von Willebrand disease): Newly added Phase 3 asset from the Vega deal — first commentary on integration and development timelines. - Niktimvo + Jakafi combo data in frontline chronic GVHD expected before year-end, which could accelerate a steroid-free regimen strategy.
INCY shares are up roughly 17% year-to-date (from ~$101 in early January to ~$119 on July 27), though they trailed the broader biotech sector (XBI) over the same period, which rose closer to 24%. However, INCY has notably outpaced the sector since mid-June, coinciding with the CMS settlement and Vega acquisition announcements — suggesting the market has already begun pricing in both the one-time GAAP benefit and the strategic pipeline broadening. This raises the bar for tomorrow's print: a "reaffirm and beat" quarter may already be reflected in the share price, making updated full-year guidance (especially net sales and margin trajectory post-settlement) and incremental pipeline commentary the more important swing factors.
Incyte enters Q2 earnings with strong underlying commercial momentum, a significant one-time GAAP tailwind from the CMS settlement, and an increasingly de-risked, broadening late-stage pipeline spanning hematology, oncology, and immunology. The core investment debate is less about the quarter itself — which should show continued double-digit net sales growth and a GAAP EPS boost from the ~$246 million settlement benefit — and more about whether management's updated 2026 guidance and pipeline commentary can justify a stock that has already re-rated meaningfully higher since the last report.